Literature DB >> 23978377

The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells.

Liangjuan Fang1, Daniel E Lowther, Matthew L Meizlish, Richard C E Anderson, Jeffrey N Bruce, Lesley Devine, Anita J Huttner, Steven H Kleinstein, Jae-Yun Lee, Joel N H Stern, Gur Yaari, Laura Lovato, Katharine M Cronk, Kevin C O'Connor.   

Abstract

BACKGROUND: Meningiomas often harbor an immune cell infiltrate that can include substantial numbers of T and B cells. However, their phenotype and characteristics remain undefined. To gain a deeper understanding of the T and B cell repertoire in this tumor, we characterized the immune infiltrate of 28 resected meningiomas representing all grades.
METHODS: Immunohistochemistry was used to grossly characterize and enumerate infiltrating lymphocytes. A molecular analysis of the immunoglobulin variable region of tumor-infiltrating B cells was used to characterize their antigen experience. Flow cytometry of fresh tissue homogenate and paired peripheral blood lymphocytes was used to identify T cell phenotypes and characterize the T cell repertoire.
RESULTS: A conspicuous B and T cell infiltrate, primarily clustered in perivascular spaces, was present in the microenvironment of most tumors examined. Characterization of 294 tumor-infiltrating B cells revealed clear evidence of antigen experience, in that the cardinal features of an antigen-driven B cell response were present. Meningiomas harbored populations of antigen-experienced CD4+ and CD8+ memory/effector T cells, regulatory T cells, and T cells expressing the immune checkpoint molecules PD-1 and Tim-3, indicative of exhaustion. All of these phenotypes were considerably enriched relative to their frequency in the circulation. The T cell repertoire in the tumor microenvironment included populations that were not reflected in paired peripheral blood.
CONCLUSION: The tumor microenvironment of meningiomas often includes postgerminal center B cell populations. These tumors invariably include a selected, antigen-experienced, effector T cell population enriched by those that express markers of an exhausted phenotype.

Entities:  

Keywords:  B cell; T cell; meningioma; tumor-infiltrating lymphocytes

Mesh:

Year:  2013        PMID: 23978377      PMCID: PMC3813416          DOI: 10.1093/neuonc/not110

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  62 in total

1.  Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.

Authors:  Robert M Prins; Horacio Soto; Vera Konkankit; Sylvia K Odesa; Ascia Eskin; William H Yong; Stanley F Nelson; Linda M Liau
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

Review 2.  CD20+ B cells: the other tumor-infiltrating lymphocytes.

Authors:  Brad H Nelson
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

Review 3.  Potential targets for pancreatic cancer immunotherapeutics.

Authors:  Lindzy F Dodson; William G Hawkins; Peter Goedegebuure
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

4.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

Review 5.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

Review 6.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Authors:  William Humphries; Jun Wei; John H Sampson; Amy B Heimberger
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

7.  Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.

Authors:  Karen S Sfanos; Tullia C Bruno; Alan K Meeker; Angelo M De Marzo; William B Isaacs; Charles G Drake
Journal:  Prostate       Date:  2009-11-01       Impact factor: 4.104

8.  Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

Authors:  Joannes F M Jacobs; Albert J Idema; Kalijn F Bol; Stefan Nierkens; Oliver M Grauer; Pieter Wesseling; J André Grotenhuis; Peter M Hoogerbrugge; I Jolanda M de Vries; Gosse J Adema
Journal:  Neuro Oncol       Date:  2008-11-21       Impact factor: 12.300

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 10.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.

Authors:  M J M Gooden; G H de Bock; N Leffers; T Daemen; H W Nijman
Journal:  Br J Cancer       Date:  2011-05-31       Impact factor: 7.640

View more
  28 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.

Authors:  John W Rutland; Corey M Gill; Joshua Loewenstern; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Raj K Shrivastava; Mary Fowkes
Journal:  Cancer Immunol Immunother       Date:  2020-07-13       Impact factor: 6.968

3.  PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.

Authors:  Dimitrios Mathios; Jacob Ruzevick; Christopher M Jackson; Haiying Xu; Sagar R Shah; Janis M Taube; Peter C Burger; Edward F McCarthy; Alfredo Quinones-Hinojosa; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2014-10-28       Impact factor: 4.130

4.  Systemic and local immunosuppression in patients with high-grade meningiomas.

Authors:  Yuping D Li; Dorina Veliceasa; Jason B Lamano; Jonathan B Lamano; Gurvinder Kaur; Dauren Biyashev; Craig M Horbinski; Tim J Kruser; Orin Bloch
Journal:  Cancer Immunol Immunother       Date:  2019-04-27       Impact factor: 6.968

Review 5.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

6.  Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.

Authors:  Caroline M Reed; Nicole D Cresce; Ileana S Mauldin; Craig L Slingluff; Walter C Olson
Journal:  Clin Cancer Res       Date:  2015-05-12       Impact factor: 12.531

7.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

8.  Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma.

Authors:  Laura Pinton; Samantha Solito; Elena Masetto; Marina Vettore; Stefania Canè; Alessandro Della Puppa; Susanna Mandruzzato
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

Review 9.  Meningioma Tumor Microenvironment.

Authors:  Sajad Sahab-Negah; Ali Gorji
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Sex-, stress-, and sympathetic post-ganglionic-dependent changes in identity and proportions of immune cells in the dura.

Authors:  Lisa A McIlvried; J Agustin Cruz; Lisa A Borghesi; Michael S Gold
Journal:  Cephalalgia       Date:  2016-07-11       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.